Atara Biotherapeutics, Inc.
ATRA
$9.81
$1.0311.73%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 73.17% | 80.36% | 112.53% | 219.71% | 79.00% |
| Total Depreciation and Amortization | -4.64% | -178.37% | -82.26% | 29.04% | -8.71% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -114.34% | -66.85% | -72.94% | 13.52% | -40.88% |
| Change in Net Operating Assets | 91.19% | -220.04% | -277.51% | -599.85% | -207.89% |
| Cash from Operations | 76.72% | -145.35% | 31.25% | 4.98% | 51.45% |
| Capital Expenditure | -- | -- | -- | -- | -104.55% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 127.50% | 85.21% | -175.00% | 15.86% | -65.30% |
| Cash from Investing | 150.00% | 85.47% | -170.46% | 16.86% | -66.05% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | 100.00% | 100.00% | -10.13% | -9.30% |
| Issuance of Common Stock | -70.74% | -- | -98.92% | -- | 2,836.88% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 70.79% | -101.28% | 8,416.85% | -- | -- |
| Cash from Financing | 99.09% | -97.07% | 4,823.46% | -101.04% | -121.69% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 112.79% | -173.72% | 177.29% | -221.01% | 45.00% |